Loading…
BALAXI PHARMACEUTICALS (BALAXI)₹22.66+1.43%Pharmaceuticals
At the end of the Jun 2026 quarter, BALAXI PHARMACEUTICALS' shareholders were: promoters 66.03%, DIIs 2.57%, public 31.40%. Promoter holding is unchanged on the quarter. 0.00% of promoter shares were pledged. It had 14,679 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 71.26% | 71.26% | 66.90% | 66.03% | 66.03% | 66.03% | 66.03% | 66.03% | 66.03% | 66.03% | 66.03% | 66.03% |
| FIIs | 18.59% | 18.59% | 17.23% | 16.90% | 16.50% | 16.50% | 16.04% | 8.89% | 3.51% | 1.75% | 0.00% | 0.00% |
| DIIs | 0.03% | 0.03% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 2.57% | 2.57% |
| Public | 10.12% | 10.12% | 15.85% | 17.05% | 17.45% | 17.45% | 17.91% | 25.06% | 30.44% | 32.20% | 31.40% | 31.40% |
| Promoter shares pledged | — | — | — | — | — | — | — | — | — | — | — | 0.00% |
| Number of shareholders | 5,046 | 5,044 | 5,205 | 6,585 | 7,861 | 8,527 | 9,992 | 13,734 | 14,617 | 15,082 | 15,173 | 14,679 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| Balaxi Overseas Private Limited | Promoter | 63.39% | 0.00 |
| Rgsl Investment Fund - Rgsl Investment Lvf 1 | DII | 2.56% | 0.00 |
| Kunal Mahendra Bhakta | Public | 1.87% | 0.00 |
| Ashish Maheshwari | Promoter | 1.65% | 0.00 |
| Key Managerial Personnel | Public | 1.42% | 0.00 |
| Amol Anand Mantri | Public | 1.40% | 0.00 |
| P P Zibi Jose | Public | 1.28% | 0.00 |
| Minoshi Maheshwari | Promoter | 0.96% | 0.00 |
| Investor Education and Protection Fund (IEPF) | Public | 0.70% | 0.00 |
Promoters held 66.03% of BALAXI PHARMACEUTICALS at the end of the Jun 2026 quarter, the same as a year earlier.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held 0.00% (unchanged at 0.00% a quarter earlier) and domestic institutions (DIIs) held 2.57% (unchanged at 2.57% a quarter earlier).
No. The Jun 2026 filing shows no pledged promoter shares.
BALAXI PHARMACEUTICALS had 14,679 shareholders at the end of the Jun 2026 quarter, against 13,734 a year earlier.
Rgsl Investment Fund - Rgsl Investment Lvf 1 (DII) held 2.56% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.